See more : Doric Nimrod Air Three Limited (DNA3.L) Income Statement Analysis – Financial Results
Complete financial analysis of Think Research Corporation (THKKF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Think Research Corporation, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS) Income Statement Analysis – Financial Results
- SenesTech, Inc. (SNES) Income Statement Analysis – Financial Results
- PT Ekadharma International Tbk (EKAD.JK) Income Statement Analysis – Financial Results
- Silk Road Energy Services Group Limited (8250.HK) Income Statement Analysis – Financial Results
- Centrica plc (CPYYF) Income Statement Analysis – Financial Results
Think Research Corporation (THKKF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.thinkresearch.com/ca/
About Think Research Corporation
Think Research Corporation, together with its subsidiaries, gathers, develops, and delivers knowledge-based Software-as-a-Service solutions for the health care industry in Canada, the United States, and internationally. The company's products portfolio comprises order sets that structures clinical pathway at the point of care; eReferrals that allows physicians to find and refer specialists directly from EMR systems; VirtualCare, which allows clinicians and allied health professionals to replace in-person appointments with virtual visits; and eForms, a real-time analytics to track resident volumes, signature adherence, and compliance; and COVID-19 clinical tools, as well as clinical support tools for long-term care. Think Research Corporation is based in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 78.60M | 47.79M | 19.44M |
| Cost of Revenue | 41.22M | 23.39M | 7.51M |
| Gross Profit | 37.39M | 24.40M | 11.93M |
| Gross Profit Ratio | 47.56% | 51.05% | 61.36% |
| Research & Development | 6.78M | 6.57M | 4.45M |
| General & Administrative | 26.96M | 23.01M | 10.68M |
| Selling & Marketing | 9.09M | 8.65M | 3.70M |
| SG&A | 36.05M | 31.66M | 14.38M |
| Other Expenses | 0.00 | 0.00 | 309.00K |
| Operating Expenses | 57.23M | 46.22M | 20.79M |
| Cost & Expenses | 98.45M | 69.61M | 28.30M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.98M | 2.05M | 1.49M |
| Depreciation & Amortization | 14.40M | 7.99M | 1.96M |
| EBITDA | -5.44M | -13.83M | -6.90M |
| EBITDA Ratio | -6.92% | -28.94% | -35.49% |
| Operating Income | -19.84M | -21.82M | -8.86M |
| Operating Income Ratio | -25.24% | -45.65% | -45.55% |
| Total Other Income/Expenses | -4.09M | -6.64M | 305.00K |
| Income Before Tax | -27.91M | -30.51M | -10.04M |
| Income Before Tax Ratio | -35.50% | -63.84% | -51.64% |
| Income Tax Expense | -2.16M | -1.46M | -24.00K |
| Net Income | -25.74M | -29.05M | -10.02M |
| Net Income Ratio | -32.75% | -60.78% | -51.51% |
| EPS | -0.42 | -0.62 | -0.28 |
| EPS Diluted | -0.42 | -0.62 | -0.28 |
| Weighted Avg Shares Out | 60.87M | 46.75M | 35.87M |
| Weighted Avg Shares Out (Dil) | 60.87M | 46.75M | 35.87M |
Think Research amends certain terms relating to previously completed acquisition of BioPharma Services
Think Research amends debt facility with ScotiaBank; ends market-making agreement with PI Financial
Think Research appoints business veteran John Hayes as permanent CFO; promotes Patrick Craib to COO role
Think Research subsidiary inks new contracts valued at C$12.8M in 3Q
Think Research expands content and learning management contract with global pharma company to $6.4M
Think Research reports 80% year-over-year surge in 2Q revenue
Think Research Announces Date of Second Quarter 2022 Earnings Release and Conference Call Details
Think Research signs contract to provide Care Pathways nursing content to St. George's University Hospitals
Think Research Corporation wins contract from major US pharmacy to deliver business intelligence and support solutions
Think Research says its subsidiary BioPharma Services achieves another successful FDA inspection result
Source: https://incomestatements.info
Category: Stock Reports